GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » BioNexus Gene Lab Corp (NAS:BGLC) » Definitions » Change In Receivables

BioNexus Gene Lab (BioNexus Gene Lab) Change In Receivables : $0.16 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is BioNexus Gene Lab Change In Receivables?

BioNexus Gene Lab's change in receivables for the quarter that ended in Mar. 2024 was $-0.11 Mil. It means BioNexus Gene Lab's Accounts Receivable increased by $0.11 Mil from Dec. 2023 to Mar. 2024 .

BioNexus Gene Lab's change in receivables for the fiscal year that ended in Dec. 2023 was $0.61 Mil. It means BioNexus Gene Lab's Accounts Receivable declined by $0.61 Mil from Dec. 2022 to Dec. 2023 .

BioNexus Gene Lab's Accounts Receivable for the quarter that ended in Mar. 2024 was $0.84 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. BioNexus Gene Lab's Days Sales Outstanding for the three months ended in Mar. 2024 was 32.18.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. BioNexus Gene Lab's liquidation value for the three months ended in Mar. 2024 was $5.18 Mil.

BioNexus Gene Lab Change In Receivables Historical Data

The historical data trend for BioNexus Gene Lab's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNexus Gene Lab Change In Receivables Chart

BioNexus Gene Lab Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Receivables
Get a 7-Day Free Trial 0.01 0.44 0.64 0.55 0.61

BioNexus Gene Lab Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.34 -0.01 0.21 0.07 -0.11

BioNexus Gene Lab Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.16 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioNexus Gene Lab  (NAS:BGLC) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

BioNexus Gene Lab's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.84/2.382*91
=32.18

2. In Ben Graham's calculation of liquidation value, BioNexus Gene Lab's accounts receivable are only considered to be worth 75% of book value:

BioNexus Gene Lab's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=5.832-1.817+0.75 * 0.84+0.5 * 1.077
=5.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioNexus Gene Lab Change In Receivables Related Terms

Thank you for viewing the detailed overview of BioNexus Gene Lab's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

BioNexus Gene Lab (BioNexus Gene Lab) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » BioNexus Gene Lab Corp (NAS:BGLC) » Definitions » Change In Receivables
Comparable Companies
NMGX CNEY CBNT HYDI COWI AMRSQ SNES CRKN ETCK PVNNF LIN XPAR:AI APD SHW ECL SHSE:600309 XSWX:SIKA BOM:500820 DD XSWX:GIVN
Traded in Other Exchanges
N/A
Address
No. 8 Jalan Kerinchi, The Vertical Business Suite II, Unit 02, Level 10, Tower B, Avenue 3, Bangar South, Kuala Lumpur, SGR, MYS, 59200
Website
https://www.bionexusgenelab.com
BioNexus Gene Lab Corp is an emerging molecular diagnostics company focused on the application of functional genomics to enable early diagnosis and personalized health management. It focuses on developing and marketing safe, effective, and non-invasive blood tests for the early detection of diseases. The company's non-invasive blood tests analyze changes in ribonucleic acid (or RNA) to detect the potentiality of 11 different diseases. These diseases include eight cancers (nasopharyngeal, lung, liver, stomach, breast, cervical, prostate, and colon), two bowel diseases (colitis and Crohn), and osteoarthritis.
Executives
Chak Hua Yew director 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Yeat Min Fong director 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Teng Fook Fong director 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Chee Keong Yap director 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Boon Teong Teoh director 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Yee Meng Wong director, officer: President 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Wei Li Leong officer: Chief Financial Officer 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Chai Ping Lin director 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Tai Tan Liong director, officer: Chief Operating Officer 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Sook Keng Yeoh director, officer: Chief Executive Officer 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200